Author:
Specchia G.,Pastore D.,Carluccio P.,Spinosa G.,Giannoccaro M.,Rizzi R.,Mestice A.,Liso V.
Publisher
Springer Science and Business Media LLC
Subject
Hematology,General Medicine
Reference18 articles.
1. Alvarado Y, Tsimberidou A, Kantarjian H, Cortes J, Garcia-Manero G, Faderl S, Thomas D, Estey E, Giles FJ (2002) Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukaemia. Cancer Chemother Pharmacol 51:87–90
2. Angelov L, Brandwein J, Baker M (1991) Results of therapy for acute myeloid leukemia in first relapse. Leuk Lymphoma 6:15–24
3. Apostolidou E, Cortes J, Tsimberidou A, Estey E, Kantarjian H, Giles F (2003) Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia. Leuk Res 27:887–891
4. Bernestein ID (2000) Monoclonal antibodies to the myeloid stem cell: therapeutic implication of CMA-676, a humanized anti-CD33 antibody calicheamicin conjugate. Leukemia 14:474–475
5. Bross P, Beitz J, Chen G, Chen XH, Duffy E, Kieffer L, Roy S, Sridhara R, Rahman A, Willliams G, Pazdur R (2001) Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 7:1490–1496
Cited by
19 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献